DENVER – Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis.

DENVER – Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Patients receiving tyrosine kinase inhibitors (TKIs) targeting EGFR mutations had a longer overall survival (OS) than those who did not receive TKIs, demonstrating the effectiveness of TKIs for LM therapy.

August 2016 Newsletter

Every day I spend in my lung cancer clinic I see happy and sad stories.

DENVER – After nearly 30 years of IASLC membership and a career in groundbreaking research, the IASLC proudly recognizes Dr. Giorgio V. Scagliotti, President-Elect of IASLC, Professor and Chair of Medical Oncology at the University of Turin and San Luigi Hospital in Italy, who recently received the 2016 Addario Lectureship Award.

DENVER – Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. Collectively, these findings illustrate the potential and reach of liquid biopsies in both identifying patients suitable for targeted treatment as well as predicting cancer recurrence.

DENVER – Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.